Literature DB >> 16763975

Extrapyramidal symptoms in Wilson's disease are associated with olfactory dysfunction.

Antje Mueller1, Ulrike Reuner, Basile Landis, Hagen Kitzler, Heinz Reichmann, Thomas Hummel.   

Abstract

Wilson's disease is a rare autosomal recessive disorder characterized by the accumulation of copper, mainly in the liver and the brain. As copper accumulation in the brain leads to disturbances in basal ganglia function, neurological-type patients typically present with hypo- and hyperkinetic extrapyramidal symptoms, with Parkinsonism being very common. Although there are numerous reports on olfactory deficits in primary neurodegenerative disorders, olfactory function has not been investigated in metabolic disorders presenting with extrapyramidal features. Twenty-four patients with Wilson's disease participated in the investigation. All patients were treated pharmacologically. They comprised patients with liver disease alone (including mild enzyme elevation in asymptomatic individuals; n = 11) and/or neurological symptoms (n = 13) at the time of testing. Twenty-one patients underwent both [18F]fluoro-2-deoxy-D-glucose positron emission tomography ([18F]FDG-PET) and magnetic resonance imaging (MRI). The severity of extrapyramidal symptoms was judged using a clinical score system ranging from 0 (no symptoms) to 3 (severe symptoms). In all patients, psychophysical testing was performed using the Sniffin' Sticks, which involved tests for odor threshold, discrimination, and identification. Results from the present study revealed that Wilson's disease patients with neurological symptoms show a significant olfactory dysfunction compared to hepatic-type patients. Individuals who are more severely neurologically affected also present with a more pronounced olfactory deficit. Of interest, there was no significant effect of long-term treatment with penicillamine on olfactory function. Olfactory function did not correlate significantly with the presence of MRI visible lesions in the basal ganglia or with any regional glucose metabolism as measured by [18]F-FDG-PET. In conclusion, these findings indicate that the underlying pathological alterations with degeneration in the basal ganglia and neuronal loss in association with a marked increase of the copper content in this brain region play a role in the olfactory deficit.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16763975     DOI: 10.1002/mds.20989

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  12 in total

Review 1.  Neurologic impairment in Wilson disease.

Authors:  Petr Dusek; Tomasz Litwin; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

2.  Olfactory function and olfactory bulb volume in Wilson's disease.

Authors:  Nazan Degirmenci; Bayram Veyseller; Hasmet Hanagasi; Basar Bilgic; Defne Gurbuz; Ali Toprak; Orhan Ozturan
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-11-22       Impact factor: 2.503

3.  [Olfactory dysfunction in neurodegenerative disorders].

Authors:  A Hähner; A Welge-Lüssen
Journal:  HNO       Date:  2010-07       Impact factor: 1.284

4.  The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism.

Authors:  Tommaso Bovi; Angelo Antonini; Sarah Ottaviani; Angela Antonioli; Maria Paola Cecchini; Vincenzo Di Francesco; Maria Antonietta Bassetto; Mauro Zamboni; Antonio Fiaschi; Giuseppe Moretto; Andrea Sbarbati; Francesco Osculati; Michele Tinazzi
Journal:  J Neurol       Date:  2010-07-16       Impact factor: 4.849

Review 5.  Olfactory dysfunction: common in later life and early warning of neurodegenerative disease.

Authors:  Karl-Bernd Hüttenbrink; Thomas Hummel; Daniela Berg; Thomas Gasser; Antje Hähner
Journal:  Dtsch Arztebl Int       Date:  2013-01-07       Impact factor: 5.594

6.  Neuroleptic-induced parkinsonism is associated with olfactory dysfunction.

Authors:  Stephanie Krüger; Antje Haehner; Claudia Thiem; Thomas Hummel
Journal:  J Neurol       Date:  2008-09-03       Impact factor: 4.849

7.  Olfactory loss in Parkinson's disease.

Authors:  Antje Haehner; Thomas Hummel; Heinz Reichmann
Journal:  Parkinsons Dis       Date:  2011-04-21

8.  Simultaneous monitoring of cerebral metal accumulation in an experimental model of Wilson's disease by laser ablation inductively coupled plasma mass spectrometry.

Authors:  Sorina Georgiana Boaru; Uta Merle; Ricarda Uerlings; Astrid Zimmermann; Sabine Weiskirchen; Andreas Matusch; Wolfgang Stremmel; Ralf Weiskirchen
Journal:  BMC Neurosci       Date:  2014-08-20       Impact factor: 3.288

9.  Olfactory impairment in Wilson's disease.

Authors:  Lei Chen; Xin Wang; Richard L Doty; Shanshan Cao; Junxiu Yang; Feng Sun; Xiaoyan Yan
Journal:  Brain Behav       Date:  2021-01-07       Impact factor: 2.708

10.  Assessment of Extrapyramidal Symptoms Associated with Psychotropics Pharmacological Treatments, and Associated Risk Factors.

Authors:  Dania Abu-Naser; Sara Gharaibeh; Ahmad Z Al Meslamani; Qais Alefan; Renad Abunaser
Journal:  Clin Pract Epidemiol Ment Health       Date:  2021-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.